Brokerage : Shinhan Securities
Analyst : Hochul Lee (Senior Analyst), Minyong Eom (Analyst)
Investment Rating : BUY (Maintained)
Target Price : KRW 1,800,000 (Maintained)
Core Momentum : Driven by commercial ramp-ups at Plant 5 and the Rockville facility starting in 3Q alongside an upgraded 20% annual revenue growth guidance, mid-to-long term expansion is reinforced by entering the high-growth peptide CDMO market through the PolyPeptide Group acquisition.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY rating maintained; Target Price maintained at KRW 1,800,000 (30.5% upside potential).
- Valuation & Guidance Outlook: Consistent operating cash flows support simultaneous capacity scaling and modality diversification. The current guidance includes only 2Q output from the Rockville site, leaving potential for further upward revisions depending on 3Q manufacturing performance.
- Annual Financial Forecast (K-IFRS Consolidated):
- 2024: Revenue KRW 3.4971 trillion, Operating Profit KRW 1.3214 trillion, Net Profit (Controlling) KRW 1.0510 trillion, P/E 94.6x, ROE 12.0%, P/B 10.7x, EV/EBITDA 41.6x.
- 2025: Revenue KRW 4.5570 trillion, Operating Profit KRW 2.0681 trillion, Net Profit (Controlling) KRW 1.5862 trillion, P/E 71.8x, ROE 19.0%, P/B 10.6x, EV/EBITDA 32.0x.
- 2026(E): Revenue KRW 5.5282 trillion, Operating Profit KRW 2.4248 trillion, Net Profit (Controlling) KRW 1.8519 trillion, P/E 34.3x, ROE 22.2%, P/B 6.9x, EV/EBITDA 22.3x.
- 2027(E): Revenue KRW 6.8517 trillion, Operating Profit KRW 3.1499 trillion, Net Profit (Controlling) KRW 2.3963 trillion, P/E 26.5x, ROE 22.9%, P/B 5.4x, EV/EBITDA 17.0x.
- 2028(E): Revenue KRW 7.5340 trillion, Operating Profit KRW 3.4975 trillion, Net Profit (Controlling) KRW 2.6664 trillion, P/E 23.8x, ROE 20.5%, P/B 4.4x, EV/EBITDA 14.9x.
🚀 2. [Market Opportunities & Business Outlook]
- 2Q26 Provisional Results Review (Record Quarterly Performance):
- Consolidated Revenue reached KRW 1.3209 trillion (+30.2% YoY), Operating Profit reached KRW 586.4 billion (+22.9% YoY, OPM 44.4%), and Net Profit reached KRW 430.7 billion (+29.1% YoY), meeting market consensus.
- Continuous full utilization across Plants 1–4 and favorable foreign exchange tailwinds drove top-line growth.
- Successfully defended a mid-40% operating margin despite upfront cost recognition for Plant 5 and the Rockville facility.
- Guidance Upgrade & Second-Half Operational Outlook:
- Upgraded full-year revenue growth guidance to +20% YoY (from previously +15~20%).
- Revenue contribution expands as Plant 5 completes test runs and transitions into PPQ validation batch production.
- Commercial revenue recognition starts in 3Q for the Rockville site after completing post-acquisition quality inspections (projected at ~KRW 100 billion quarterly, contributing up to KRW 500 billion annually).
- Modality Diversification via PolyPeptide Group Acquisition:
- Signed an agreement on July 18 to acquire Switzerland-based PolyPeptide Group (~KRW 2.7 trillion deal value; targeting transaction closing within the year).
- PolyPeptide is a global CDMO leader with proven experience across 1,000+ peptide therapeutics.
- Positions the company for direct entry into the surging GLP-1 obesity/diabetes peptide market (financing structure including borrowings, corporate bonds, or rights offering to be monitored).
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics not as a business constrained by upfront operational costs, but as an aggressive global biomanufacturing powerhouse executing simultaneous capacity expansion (Plant 5 and US Rockville) and strategic modality diversification (PolyPeptide Group acquisition) into high-demand GLP-1 peptide treatments. The perspective highlights the qualitative transition of the business model, driven by synchronized capacity scaling and rapid footprint entry into high-growth therapeutic markets rather than temporary upfront cost burdens.
To verify whether this investment thesis unfolds as anticipated, key monitoring variables include the actual quarterly revenue ramp-up from the Rockville facility (~KRW 100 billion/quarter target) and Plant 5 starting in 3Q, potential additional full-year guidance upgrades based on 3Q results, and the definitive closing of the PolyPeptide Group transaction alongside its finalized funding mix (debt, corporate bonds, or equity issuance). These developments can be tracked through upcoming quarterly earnings releases, investor presentations, and regulatory filings on DART.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
